Eli Lilly and Co.: Drug Development Strategy (A) Harvard Case Solution & Analysis

Describes how Eli Lilly and Co. is trying to speed up the development of new products with the help of "combinatorial chemistry" - a rapidly developing and revolutionary approach to the pre-clinical drug development. Product Manager at potential blockbuster drugs migraine faced with the decision "Racing" drug on the market, or spend the extra time to improve is a promising drug candidate. Focused on: (1) a new process of drug development, with a focus on pre-clinical medicine, (2) radical innovations ("combinatorial chemistry") in the drug discovery process, and (3) the management problems of introducing such innovations in a large organization with multiple stakeholders ( 4) the financial value of time-to-market.;, (5) changes in the competitive environment in the pharmaceutical industry "Hide
by Stefan Thomke, Ashok Paul Pospisil Nimgade Source: Harvard Business School 25 pages. Publication Date: 04 Oct 1997. Prod. #: 698010-PDF-ENG

Eli Lilly and Co.:  Drug Development Strategy (A) Case Solution Other Similar Case Solutions like

Eli Lilly and Co.: Drug Development Strategy (A)

Share This